Innovative Plant-Based Medicine Set to Transform Inflammatory
Disease Treatments in the US Market
LONDON, March 22, 2023 /PRNewswire/ -- MGC
Pharmaceuticals Ltd. (LSE: MXC), (ASX: MXC), (OTC: MGCLF), a
European based bio-pharma company specializing in the development
and supply of affordable, ethically produced plant-inspired
medicines, announces that its innovative product ArtemiC™ has
recently been listed as an over-the-counter (OTC) drug in the
USA on the FDA National Drug Code
(NDC) Database under the code 83278. Facilitated by the company's
US-based supply and distribution partner, AMCPharma USA, LLC. (AMC), ArtemiC™ will be available in
US Pharmacy Benefit Management (PBM) networks starting April 2023, with ongoing discussions for its
inclusion in other independent outlets.
In response to the NDC listing, AMC has placed a US$2 million purchase order for ArtemiC™, with
production set to commence immediately. Delivery is scheduled in
two installments in Q3 and Q4 of this year. ArtemiC™, which
completed a successful Phase II Clinical Trial in 2020, has
demonstrated significant benefits for patients suffering from
moderate COVID-19. Subsequent trials have proven its effectiveness
as an anti-inflammatory treatment across a wide range of chronic
diseases.
Brent W. Yessin of AMC expressed
his enthusiasm, "We are pleased to have secured the NDC for MGC
Pharma's proprietary product, ArtemiC™, which we believe will make
a considerable impact in the over-the-counter retail sector. Our
partnership with MGC enables us to offer the market a clinically
proven, plant-based, FDA-authorized product that fills an important
gap between existing OTC products and expensive prescription
products from Big Pharma."
Roby Zomer, CEO and Managing
Director of MGC Pharmaceuticals, added, "The listing of ArtemiC™ as
an over-the-counter drug provides significant access to the largest
healthcare market in the world and stands as a major milestone in
MGC's growth progression. The receipt of a US$2 million order from our distribution partner,
AMC, is a strong endorsement for the product, which has
demonstrated the capacity to relieve symptoms of COVID-19 and other
inflammatory diseases."
ArtemiC™, an all-natural product developed by MGC Pharma in
collaboration with partner Swiss PharmaCan AG and Grat Bio® SNEDD
technology, increases the bioavailability of its active ingredients
at the cellular level. The versatile treatment has shown a full
safety and efficacy profile with no drug-adverse events and can be
used in community settings and hospitals alike.
HTTP://MGCpharma.eu
Twitter: @MGC_Pharma
Facebook: @mgcpharmaceuticals
Logo -
https://mma.prnewswire.com/media/1780050/mgcpharma_logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/artemic-tm-listed-as-an-otc-drug-in-the-usa-amc-places-us2m-order-301778304.html